Ubrogepant During Prodromal Phase of Migraine Eases Symptoms

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 13, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, May 13, 2025 -- Ubrogepant during the prodromal phase of migraine may alleviate common prodromal symptoms, according to a study published online May 12 in Nature Medicine.

Peter J. Goadsby, M.B.B.S., M.D., Ph.D., from King's College London, and colleagues conducted a phase 3, placebo-controlled trial to examine whether ubrogepant 100 mg dosed during the premonitory (prodromal) phase of migraine prevented headache development and resolved prodromal symptoms. Qualifying prodromal events were defined as attacks with symptoms in which the patient was confident that headache would occur within one to six hours. The efficacy analysis population included 477 patients.

The researchers found that absence of photophobia at two hours postdose occurred in 19.5 and 12.5 percent of ubrogepant- and placebo-treated events, respectively (odds ratio, 1.72). At three hours postdose, absence of fatigue occurred in 27.3 and 16.8 percent, and absence of neck pain occurred in 28.9 and 15.9 percent of events, respectively (odds ratios, 1.85 and 2.04, respectively). Absence of phonophobia occurred in 50.7 and 35.8 percent of events at four hours postdose (odds ratio, 1.97); and at 24 hours post-dose, absence of dizziness occurred in 88.5 and 82.3 percent of events (odds ratio, 1.82). Absence of difficulty concentrating occurred in 8.7 and 2.1 percent of events at one and six hours postdose, while absence of difficulty thinking occurred in 56.9 and 41.8 percent of events (odds ratios, 4.26 and 2.05, respectively).

"Ubrogepant 100 mg, when administered in the premonitory (prodromal) phase of migraine, before a headache has commenced, may treat symptoms such as photophobia, phonophobia, and cognitive dysfunction," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including AbbVie, which manufactures ubrogepant and funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-14 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords